Evaluation of the LTK63 adjuvant effect on cellular immune responses to measles virus nucleoprotein
Background: A lot of pathogens enter the body via the nasal route. The construction of non-toxic mutants of heat labile Escherichia coli enterotoxin (LT), which is a potent mucosal adjuvant, represents a major breakthrough for the development of mucosal vaccines. Objective: This study was undertaken...
Gespeichert in:
Veröffentlicht in: | African health sciences 2011-06, Vol.11 (2), p.151-157 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background: A lot of pathogens enter the body via the nasal route. The
construction of non-toxic mutants of heat labile Escherichia coli
enterotoxin (LT), which is a potent mucosal adjuvant, represents a
major breakthrough for the development of mucosal vaccines. Objective:
This study was undertaken to critically evaluate the adjuvanticity of
the mutant of LT (LTK63) on the cellular immune responses to
intranasally co-administered recombinant measles virus nucleoprotein
(rMVNP). Methods: Groups of CBA mice were immunized intranasally with
rMVNP with or without LT or LTK63 as adjuvants. Another group was
immunized subcutaneously with rMVNP in Freund's adjuvant. rMVNP and
measles virus (MV) were used in a proliferation assay to test the LTK63
potentiating ability to induce T cell responses. Subsequently MVNP
synthetic peptides spanning the length of the N protein were used with
a proliferation assay to identify the T cell epitopes. Results:
Splenocytes from mice immunized intranasally with rMVNP plus LT or
LTK63, showed strong dose dependent proliferative responses to both the
MVNP and MV. However, proliferative responses from the latter group
were significantly lower than the former group (P < 0.05).
Splenocytes tested recognized peptides 20, 21, 28, 31, 39, 40 and 50,
suggesting these to be among important epitopes. Subcutaneous route was
not effective in priming for T cell responses to rMVNP. Conclusion:
These data further demonstrate the great potential of LTK63 as a safe
mucosal vaccine adjuvant. |
---|---|
ISSN: | 1680-6905 1729-0503 |